LAG3 and cutaneous melanoma: In cutaneous melanoma treated with anti–PD-1, LAG-3 positivity aligns with ICI responsiveness and longer PFS, whereas in ocular melanoma, high LAG-3 expression is instead associated with adverse outcomes.